Tevogen Bio Holdings Inc.

Tevogen Bio Holdings Inc.

Biotechnology • Healthcare • Warren, NJ, United States • TVGNW (NCM)

Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.

877 838 6436 15 Independence Boulevard, Warren, NJ 07059, United States

Stock Performance (90 Days)

Data through Dec 24, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance
Yahoo Finance • Dec 9
Tevogen CEO Donates Personal Shares to Support Local Fire Department - GlobeNewswire
GlobeNewswire • Dec 19
Tevogen Bio Holdings receives Nasdaq notice for minimum bid price deficiency - Investing.com
Investing.com • Sep 26
Tevogen Bio Holdings Inc. Recognized in 2025 New Jersey Power List for Innovation and Economic Impact - Quiver Quantitative
Quiver Quantitative • Dec 8
What drives Tevogen Bio Holdings Inc G28 stock price - Earnings Surprise Analysis & Superior Portfolio Growth - earlytimes.in
earlytimes.in • Jan 5

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has Tevogen Bio Holdings Inc. had layoffs?
No layoff events have been recorded for Tevogen Bio Holdings Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does Tevogen Bio Holdings Inc. have?
Tevogen Bio Holdings Inc. has approximately 18 employees.
What industry is Tevogen Bio Holdings Inc. in?
Tevogen Bio Holdings Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is Tevogen Bio Holdings Inc. a publicly traded company?
Yes, Tevogen Bio Holdings Inc. is publicly traded under the ticker symbol TVGNW on the NCM.
Where is Tevogen Bio Holdings Inc. headquartered?
Tevogen Bio Holdings Inc. is headquartered in Warren, NJ, United States at 15 Independence Boulevard, Warren, NJ 07059, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.